| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Çağlayan Akkaya, Serap Sahin Yavuzer, Hakan Yavuzer, Gökhan Erkol, Melda Bozluolcay, Yıldız Dinçe. DNA damage, DNA susceptibility to oxidation and glutathione redox status in patients with Alzheimer's disease treated with and without memantine. Journal of the neurological sciences. vol 378. 2018-03-14. PMID:28566155. |
the aim of the current study was to compare oxidative dna damage, dna susceptibility to oxidation, and ratio of gsh/gssg in patients with alzheimer's disease (ad) treated with acetylcholinesterase inhibitor (achei) and combined achei+memantine. |
2018-03-14 |
2023-08-13 |
human |
| Cristian A Gasca, Willian O Castillo, Catarina Satie Takahashi, Christopher W Fagg, Pérola O Magalhães, Yris M Fonseca-Bazzo, Dâmaris Silveir. Assessment of anti-cholinesterase activity and cytotoxicity of cagaita (Eugenia dysenterica) leaves. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. vol 109. issue Pt 2. 2018-03-12. PMID:28238772. |
the extract and two isolated compounds were also assessed for the potential inhibitory activity on acetylcholinesterase, an enzyme related to alzheimer's disease. |
2018-03-12 |
2023-08-13 |
human |
| Ilkay Erdogan Orhan, Fatma Sezer Senol, Suhaib Shekfeh, Krystyna Skalicka-Wozniak, Erden Banogl. Pteryxin - A promising butyrylcholinesterase-inhibiting coumarin derivative from Mutellina purpurea. Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association. vol 109. issue Pt 2. 2018-03-12. PMID:28286309. |
in this study, pteryxin, which was previously isolated from the fruits of mutellina purpurea, was investigated for its inhibitory potential against acetylcholinesterase (ache) and butyrylcholinesterase (bche), which are the key enzymes in the pathology of alzheimer's disease (ad). |
2018-03-12 |
2023-08-13 |
Not clear |
| Victor Bloniecki, Dag Aarsland, Kaj Blennow, Jeffrey Cummings, Farshad Falahati, Bengt Winblad, Yvonne Freund-Lev. Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid. Journal of Alzheimer's disease : JAD. vol 57. issue 2. 2018-02-26. PMID:28269767. |
antipsychotics and acetylcholinesterase inhibitors are used generating symptomatic improvements in behavior and cognition, but few studies have investigated their effect on alzheimer's disease (ad) biomarkers in cerebrospinal fluid (csf). |
2018-02-26 |
2023-08-13 |
Not clear |
| Arun Bahadur Gurung, Kripamoy Aguan, Sivaprasad Mitra, Atanu Bhattacharje. Identification of molecular descriptors for design of novel Isoalloxazine derivatives as potential Acetylcholinesterase inhibitors against Alzheimer's disease. Journal of biomolecular structure & dynamics. vol 35. issue 8. 2018-02-23. PMID:27410776. |
identification of molecular descriptors for design of novel isoalloxazine derivatives as potential acetylcholinesterase inhibitors against alzheimer's disease. |
2018-02-23 |
2023-08-13 |
Not clear |
| Pietro Gareri, Alberto Castagna, Antonino Maria Cotroneo, Daria Putignano, Raffaele Conforti, Francesco Santamaria, Saverio Marino, Salvatore Putignan. The Citicholinage Study: Citicoline Plus Cholinesterase Inhibitors in Aged Patients Affected with Alzheimer's Disease Study. Journal of Alzheimer's disease : JAD. vol 56. issue 2. 2018-02-23. PMID:28035929. |
acetylcholinesterase inhibitors (acheis) have been used for treatment of alzheimer's disease (ad). |
2018-02-23 |
2023-08-13 |
Not clear |
| Ana-Belen Cutillas, Alejandro Carrasco, Ramiro Martinez-Gutierrez, Virginia Tomas, Jose Tudel. Thymus mastichina L. essential oils from Murcia (Spain): Composition and antioxidant, antienzymatic and antimicrobial bioactivities. PloS one. vol 13. issue 1. 2018-02-23. PMID:29304179. |
all four t. mastichina eos inhibited both lipoxygenase and acetylcholinesterase activities, and they might be useful for further research into inflammatory and alzheimer diseases. |
2018-02-23 |
2023-08-13 |
Not clear |
| Sophie Sokolow, Xiaohui Li, Lucia Chen, Kent D Taylor, Jerome I Rotter, Robert A Rissman, Paul S Aisen, Liana G Apostolov. Deleterious Effect of Butyrylcholinesterase K-Variant in Donepezil Treatment of Mild Cognitive Impairment. Journal of Alzheimer's disease : JAD. vol 56. issue 1. 2018-02-21. PMID:27911294. |
in alzheimer's disease, butyrylcholinesterase (bche) activity increases with disease progression and may replace acetylcholinesterase function. |
2018-02-21 |
2023-08-13 |
Not clear |
| Pinar Atukeren, Mahir Cengiz, Hakan Yavuzer, Remise Gelisgen, Esma Altunoglu, Sena Oner, Fusun Erdenen, Damla Yuceakın, Himmet Derici, Ufuk Cakatay, Hafize Uzu. The efficacy of donepezil administration on acetylcholinesterase activity and altered redox homeostasis in Alzheimer's disease. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. vol 90. 2018-02-16. PMID:28427041. |
the efficacy of donepezil administration on acetylcholinesterase activity and altered redox homeostasis in alzheimer's disease. |
2018-02-16 |
2023-08-13 |
human |
| Pinar Atukeren, Mahir Cengiz, Hakan Yavuzer, Remise Gelisgen, Esma Altunoglu, Sena Oner, Fusun Erdenen, Damla Yuceakın, Himmet Derici, Ufuk Cakatay, Hafize Uzu. The efficacy of donepezil administration on acetylcholinesterase activity and altered redox homeostasis in Alzheimer's disease. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie. vol 90. 2018-02-16. PMID:28427041. |
we intended to investigate the effects of acetylcholinesterase inhibition via donepezil on protein carbonyl (pco), advanced protein oxidation products (aopp) and ischemia modified albumin (ima) as protein oxidation markers and ferric reducing antioxidant power (frap), prooxidant-antioxidant balance (pab), total thiol (t-sh), protein thiol (p-sh) as antioxidant status markers and also kynurenine (kyn), n-formyl kynurenine (n-fkyn) and protein bound dityrosine (dt) levels all in one demonstrating the redox homeostasis in alzheimer patients also correlated with ache activity. |
2018-02-16 |
2023-08-13 |
human |
| Georgi Stavrakov, Irena Philipova, Dimitrina Zheleva, Mariyana Atanasova, Spiro Konstantinov, Irini Doytchinov. Docking-based Design of Galantamine Derivatives with Dual-site Binding to Acetylcholinesterase. Molecular informatics. vol 35. issue 6-7. 2018-02-12. PMID:27492242. |
the enzyme acetylcholinesterase is a key target in the treatment of alzheimer's disease because of its ability to hydrolyze acetylcholine via the catalytic binding site and to accelerate the aggregation of amyloid-β peptide via the peripheral anionic site (pas). |
2018-02-12 |
2023-08-13 |
Not clear |
| Amit Kumar, Taher Darreh-Shor. DMSO: A Mixed-Competitive Inhibitor of Human Acetylcholinesterase. ACS chemical neuroscience. vol 8. issue 12. 2018-01-30. PMID:29017007. |
here, we report the detailed biochemical analysis of the effects of dmso on the human acetylcholine-degrading enzyme, acetylcholinesterase (ache), the primary target of current alzheimer's therapeutics. |
2018-01-30 |
2023-08-13 |
human |
| Thomas Desmidt, Caroline Hommet, Vincent Camu. Pharmacological treatments of behavioral and psychological symptoms of dementia in Alzheimer's disease: role of acetylcholinesterase inhibitors and memantine. Geriatrie et psychologie neuropsychiatrie du vieillissement. vol 14. issue 3. 2018-01-29. PMID:27651011. |
pharmacological treatments of behavioral and psychological symptoms of dementia in alzheimer's disease: role of acetylcholinesterase inhibitors and memantine. |
2018-01-29 |
2023-08-13 |
Not clear |
| Jeroen Jacobs, Michele Moris, Tim De Samber, Johannes Vrijdag, Wim De Borggraeve, Luc Van Meervel. The orthorhombic pseudopolymorph of tacrine hydrochloride. Acta crystallographica Section B, Structural science, crystal engineering and materials. vol 72. issue Pt 5. 2018-01-29. PMID:27698319. |
crystallization of tacrine hydrochloride, an acetylcholinesterase inhibitor used during treatment of mild to moderate alzheimer's disease, from a water:ethanol solution has resulted in an orthorhombic pseudopolymorph. |
2018-01-29 |
2023-08-13 |
Not clear |
| Maria-Letizia Campanari, Francisco Navarrete, Stephen D Ginsberg, Jorge Manzanares, Javier Sáez-Valero, María-Salud García-Aylló. Increased Expression of Readthrough Acetylcholinesterase Variants in the Brains of Alzheimer's Disease Patients. Journal of Alzheimer's disease : JAD. vol 53. issue 3. 2018-01-26. PMID:27258420. |
increased expression of readthrough acetylcholinesterase variants in the brains of alzheimer's disease patients. |
2018-01-26 |
2023-08-13 |
human |
| Maria-Letizia Campanari, Francisco Navarrete, Stephen D Ginsberg, Jorge Manzanares, Javier Sáez-Valero, María-Salud García-Aylló. Increased Expression of Readthrough Acetylcholinesterase Variants in the Brains of Alzheimer's Disease Patients. Journal of Alzheimer's disease : JAD. vol 53. issue 3. 2018-01-26. PMID:27258420. |
alzheimer's disease (ad) is characterized by a decrease in the enzymatic activity of the enzyme acetylcholinesterase (ache). |
2018-01-26 |
2023-08-13 |
human |
| Agnieszka Nikiforuk, Agnieszka Potasiewicz, Tomasz Kos, Piotr Popi. The combination of memantine and galantamine improves cognition in rats: The synergistic role of the α7 nicotinic acetylcholine and NMDA receptors. Behavioural brain research. vol 313. 2018-01-25. PMID:27435422. |
the combination of memantine and acetylcholinesterase inhibitors (acheis) is used as a therapeutic strategy to improve cognition in alzheimer's disease. |
2018-01-25 |
2023-08-13 |
rat |
| Ganiyu Oboh, Opeyemi Babatunde Ogunsuyi, Oluwaseyi Emmanuel Olonisol. Does caffeine influence the anticholinesterase and antioxidant properties of donepezil? Evidence from in vitro and in vivo studies. Metabolic brain disease. vol 32. issue 2. 2018-01-12. PMID:28091956. |
with reports of the potential cognitive enhancing properties of caffeine, we sought to investigate if caffeine can influence the anticholinesterase and antioxidant properties of donepezil-a selective acetylcholinesterase (ache) inhibitor used in the management of alzheimer's disease (ad). |
2018-01-12 |
2023-08-13 |
human |
| Lydia Giménez-Llort, Miriam Ratia, Belén Pérez, Pelayo Camps, Diego Muñoz-Torrero, Albert Badia, M Victoria Clo. Behavioural effects of novel multitarget anticholinesterasic derivatives in Alzheimer's disease. Behavioural pharmacology. vol 28. issue 2 and 3-Spec Issue. 2018-01-11. PMID:28125507. |
the current pharmacological approach to alzheimer's disease (ad) treatment, mostly based on acetylcholinesterase inhibitors (acheis), is being revisited, especially in terms of the temporal frames and the potential benefits of their noncanonic actions, raising the question of whether inhibitors of ache might also act in a disease-modifying manner. |
2018-01-11 |
2023-08-13 |
mouse |
| António José Gabriel, Maria Rosário Almeida, Maria Helena Ribeiro, João Durães, Miguel Tábuas-Pereira, Ana Cristina Pinheiro, Rui Pascoal, Isabel Santana, Inês Baldeira. Association between butyrylcholinesterase and cerebrospinal fluid biomarkers in Alzheimer's disease patients. Neuroscience letters. vol 641. 2017-12-12. PMID:28108398. |
the deficit of cholinergic activity is one of the main findings in alzheimer's disease (ad), and is related to the synthesis of acetylcholine, and the hydrolysing enzymes, acetylcholinesterase and butyrylcholinesterase (buche). |
2017-12-12 |
2023-08-13 |
Not clear |